This is an expanded access program (EAP) for eligible participants. This program isdesigned to provide access to Telisotuzumab vedotin prior to approval by the localregulatory agency. Availability will depend on territory eligibility. A medical doctormust decide whether the potential benefit outweighs the risk of receiving aninvestigational therapy based on the individual patient's medical history and programeligibility criteria.
Drug: Telisotuzumab vedotin
Intravenous Infusion
Other Name: ABBV-399
Inclusion Criteria:
- The participant must not be eligible for a telisotuzumab vedotin clinical trial.
Sutter Medical Group /ID# 254816
Sacramento, California, United States
Oncology & Hematology Specialist /ID# 248083
Mountain Lakes, New Jersey, United States
Western Heamatology and Oncology Clinics /ID# 243364
West Perth, Western Australia, Australia
University Hospital Cologne /ID# 254773
Cologne, Germany
Asklepios Fachkliniken Muenchen-Gauting /ID# 259196
Gauting, Germany
Hong Kong United Oncology Centre /ID# 241857
Yau Ma Tei, Hong Kong
The Chaim Sheba Medical Center /ID# 256530
Ramat Gan, Tel-Aviv, Israel
Shaare Zedek Medical Center /ID# 252374
Jerusalem, Israel
Rabin Medical Center /ID# 228611
Petakh Tikva, Israel
ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com
ABBVIE INC., Study Director
AbbVie